factors released from brain cells upon neonatal hypoxic-ischemic encephalopathy that potentially interact with stem cells and lead to stem cell mobilization, migration, cell adhesion and differentiation. However, the main problem with this review is that it is unclear how this discussion is relevant to endogenous and exodogenous stem cell -mediated brain repair. In the first half of the review the authors spend most of the time disscusing factors potentially impacting HSCs and MSCs. Apart from one research that uses autologous cord blood cells to treat infants with hypoxicischemic encephalopathy (which has a small sample size), no evidence was provided supporting the notion that stem cell therapy requires mobilization of endogenous HSCs and MSC, or how this process could potentially benefit the patients. Also, I am not sure if there is any evidence that implanted HSCs and MSCs need to be mobilized to reach the injured brain site to mediate neural repair.
